Table 1.
Clinical Characteristics and Outcomes of Participants With and Those Without Cytomegalovirus (CMV) Reactivation Within 100 Days After Transplantation
| Characteristic | Total (n = 63) | CMV Reactivation (n = 23) | No CMV Reactivation (n = 40) | P Value |
|---|---|---|---|---|
| Age, y | 56 (21–73) | 57 (21–69) | 56 (24–73) | .494 |
| Sex | .794 | |||
| Male | 37 (59) | 14 (61) | 23 (58) | |
| Female | 26 (41) | 9 (39) | 17 (42) | |
| Race | .549 | |||
| White | 49 (78) | 17 (74) | 32 (80) | |
| African American | 6 (10) | 3 (13) | 3 (7) | |
| Hispanic | 7 (11) | 2 (9) | 5 (13) | |
| Asian | 1 (2) | 1 (4) | 0 | |
| Cancer type | .213 | |||
| Acute leukemia | 38 (60) | 11 (48) | 27 (68) | |
| Chronic leukemia | 8 (13) | 3 (13) | 5 (12) | |
| Myelodysplastic syndrome | 17 (27) | 9 (39) | 8 (20) | |
| Transplant source or type | .148 | |||
| Match related donor | 23 (37) | 5 (22) | 18 (45) | |
| Match unrelated donor | 35 (56) | 15 (65) | 20 (50) | |
| Cord blood | 5 (8) | 3 (13) | 2 (5) | |
| Stem cell source | .375 | |||
| Peripheral | 41 (65) | 13 (57) | 28 (70) | |
| Marrow | 17 (27) | 7 (30) | 10 (25) | |
| Cord | 5 (8) | 3 (13) | 2 (5) | |
| HCT donor CMV status | .280 | |||
| CMV positive | 41 (65) | 13 (57) | 28 (70) | |
| CMV negative | 22 (35) | 10 (43) | 12 (30) | |
| Myeloablative conditioning regimen | 58 (92) | 19 (83) | 39 (98) | .055 |
| Time from HCT receipt to engraftment, mo, median (range) | 12 (10–25) | 12 (10–20) | 12 (10–25) | .358 |
| Corticosteroida use before reactivation | 19 (31) | 5 (22) | 14 (36) | .208 |
| GvHD prophylaxis regimen | ||||
| Tacrolimus | 63 (100) | 23 (100) | 40 (100) | … |
| Methotrexate | 58 (92) | 20 (87) | 38 (95) | .345 |
| Mycophenolate | 5 (8) | 3 (13) | 2 (5) | .345 |
| GvHDb (grade 1 or 2) before reactivation | 12 (19) | 4 (17) | 8 (20) | .799 |
| All-cause mortality | 8 (13) | 4 (17) | 4 (10) | .318 |
Abbreviations: CMV, cytomegalovirus; GvHD, graft-versus-host disease; HCT, hematopoietic cell transplant.
a Dose, >1 mg/kg.
b Eight patients had skin GvHD, 2 with gastrointestinal GvHD, and 2 with both sites involved.